Navigation Links
SemBioSys Genetics Inc. Announces Clinical Results with Plant-Produced Insulin
Date:3/19/2009

    SBS-1000 shown to be bioequivalent to Humulin(R) R (recombinant human
    insulin)

CALGARY, March 19 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), specializing in the manufacture of high-value proteins and oils in plant seeds, today announced preliminary results of its first "in-man" clinical study of SBS-1000, a recombinant human insulin manufactured using its proprietary platform. The trial demonstrated that SBS-1000 was bioequivalent to a recombinant human insulin with the expected safety profile.

    Highlights from the preliminary analysis were:

    -   SBS-1000 was bioequivalent to Eli Lilly's Humulin(R) R, a widely-used
        human insulin in North America, meeting all four of the endpoints
        outlined below.
    -   SBS-1000 in humans showed pharmacokinetics and pharmacodynamics
        indistinguishable from Eli Lilly's Humulin(R) R, as SemBioSys had
        previously shown in animals.
    -   SBS-1000 was well tolerated at pharmacologically active dosages.

In this single administration, double blind trial, 23 healthy volunteers were administered the same dose of SBS-1000, Humulin(R) R (recombinant human insulin marketed in the US by Eli Lilly) and Humulin(R) S (recombinant human insulin marketed in the UK by Eli Lilly) in a three way cross-over study. This euglycemic clamp study coupled insulin administration with glucose infusion to maintain the volunteers' blood sugars at baseline levels.

Preliminary data are available for the primary endpoints of 1) total insulin exposure, calculated from the measured blood levels for insulin for eight hours post-injection (AUC(insulin0to8hrs)); 2) maximum concentration of insulin (Cmax(insulin)); 3) total glucose infused over eight hours (AUC(GIR0to8hrs)); and 4) maximum glucose infusion rate (GIR(max)). Bioequivalence is declared when the comparisons between two products indicate that statistically the
'/>"/>

SOURCE SemBioSys Genetics Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SemBioSys announces senior management changes
2. SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin
3. SemBioSys begins phase I/II trial of insulin produced in plant seeds
4. SemBioSys eligible to proceed with Phase I/II plant-produced insulin trial after submission of IND
5. SemBioSys announces second quarter 2008 financial and operational results
6. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
7. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
8. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
9. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
10. SemBioSys announces first quarter 2008 financial and operational results
11. SemBioSys receives milestone payments from AVAC Ltd.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Understanding the need for better quality and higher ... that currently exists in this area, ChanTest has recently ... validated ion channel and GPCR cell lines. ChanTest’s ... channels control many critical physiological functions throughout the body. ... to treat a variety of human diseases. , ...
(Date:7/10/2014)... Unraveling life’s mysteries can intrigue, amaze, and ... purchased a DNA test to unravel the ... a lifetime of memories, sharing, and closeness. In fact, ... genuinely brought the family closer together. , Recently, ... history and prior to taking the genetic ancestry ...
(Date:7/10/2014)... OMICS Group’s 5th International conference and exhibition ... at Double Tree by Hilton Beijing, China is all ... & Bioanalytical research methods only to facilitate improved living ... Dr. Srinubabu Gedela, MD of OMICS Group Inc has ... one in bringing a unique and international mix of ...
(Date:7/10/2014)... July 10, 2014 Senior supply chain ... professional associations, addressed the challenges of “Reducing Cost, Lead ... Industries” through strategic sourcing. Describing the partnership of the ... Supply Chain Management Institute ( SCMI) of the ... June 24 at the Kroc Institute of Peace and ...
Breaking Biology Technology:Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4
... AMDL, Inc. (Amex:,ADL), with operations in Shenzhen, ... subsidiary Jade Pharmaceutical Inc. (JPI), an international,biopharma ... and,marketing of proprietary pharmaceutical and diagnostic products, ... expansion plans to increase,annualized sales in FY2008, ...
... Nov. 20 Sangamo,BioSciences, Inc. (Nasdaq: SGMO ) ... provide an update on the progress of,Sangamo,s ZFP Therapeutic ... at 11:00 am (ET) on Wednesday, November 28,2007 at ... New York. The presentation will be webcast live ...
... FOLD ) today announced that John F. Crowley, ... at the Lazard Capital,Markets Fourth Annual Healthcare Conference in ... ET at The New York Palace Hotel. A ... available to all,interested parties through the Investors section of ...
Cached Biology Technology:AMDL Launches New JPGreen Business Strategy 2Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 2Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference 3
(Date:7/13/2014)... more effective treatments for cachexia, a profound wasting of ... cancer patients, raising their risk of death, according to ... been tried to reverse the condition, which may cause ... but none have had great success. , Scientists reporting ... Nature , led by Bruce Spiegelman, PhD, demonstrated that ...
(Date:7/11/2014)... The Mills Canyon fire started near the City of ... of local resources, the fire quickly grew to over ... cause of the fire is under investigation by the ... is working with existing local resources in developing fire ... Forest Service (USFS), Washington State Department of Natural Resources, ...
(Date:7/11/2014)... Cell scientists have set a "mouse TRAP" to capture ... a recent study published in the Journal of ... a technique called TRAP to extract cellular and genetic ... by scientists at the Rockefeller Institute for Medical Research ... the protein-making machinery, or ribosomes, of the cell type ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3
... at Mount Sinai School of Medicine have discovered a ... and resistance to chemotherapy, and participate in tumor progression. ... tests for early cancer diagnosis, prognostic tests, and innovative ... Resistance to chemotherapy is a frequent ...
... The decision has been taken by the German government to ... The transition process is gaining impetus but much remains to ... wind energy is to be dramatically expanded not only ... still immense potential inland that remains to be tapped, such ...
... appreciate this fabric, which looks innocuous but in fact ... a microcontroller that detects warning signals emitted when the ... can be used to protect buildings, bank vaults, and ... parked overnight at truck stops are particularly vulnerable to ...
Cached Biology News:Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel' 2More accurate wind energy forecasts 2More accurate wind energy forecasts 3A smart fabric sets off the alarm 2A smart fabric sets off the alarm 3
...
X-Gal, 100 mg. 5-Bromo-4-chloro-3-indolyl-b-d-galactoside.Histochemical substrate for b-galactosidase, used in blue/white screening.Store at -20 C. Protect from moisture. Category: Nucleotides & Enzy...
...
RayBio L Series 507: RayBio Label-based Antibody Array I (2 membranes) Class: Antibody Array Products Product Group: Antibody Array...
Biology Products: